|Bid||0.0700 x 0|
|Ask||0.0750 x 0|
|Day's Range||0.0650 - 0.0750|
|52 Week Range||0.0500 - 0.5400|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan. 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sproutly Canada, Inc. (CSE:SPR) (OTCQB:SRUTF) (FSE:38G) ("Sproutly" or the "Company") will likely miss its filing deadline of August 12, 2020 to file annual consolidated financial statements and accompanying management's discussion and analysis and related CEO and CFO certificates for the financial period ended February 29, 2020 (collectively, the "Annual Filings"), as required under applicable Canadian securities laws.
Infusion Biosciences Inc. ("Infusion Biosciences"), a biotechnology company focused on discovering and commercializing innovative hemp and cannabis products, is pleased to announce the first commercial launch of a beverage utilizing its proprietary water-soluble hemp extract ingredient Infuz2O in the United States with KALO (www.drinkkalo.com) (the "Infuz2O Beverage Launch"). The KALO line of beverages is being serviced via a supply agreement with Whole Plant Extractions LLC, ("WPE") a joint venture between Infusion Biosciences and HillviewMed Inc. (d/b/a/Hillview) (www.HillviewMed.com). The KALO beverage line consist of flavored seltzers with a full entourage of natural hemp phytochemicals including cannabinoids, terpenes, vitamins, minerals & antioxidants with only 15 calories and five ingredients.
Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) ("Sproutly" or the "Company") announces that the Company has entered into a second supplemental indenture dated July 23, 2020 (the "Second Supplemental Indenture") between the Company and TSX Trust Company, as trustee, which amends the terms of its convertible debenture indenture dated October 24, 2018 (the "Original Indenture"), as amended by the first supplemental indenture dated April 24, 2020 (the "First Supplemental Indenture", and together with the Original Indenture, the "Indenture") providing for the issue of 8.0% senior unsecured convertible debentures in the aggregate principal amount of up to $10,750,000 (the "Debentures").